The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
<p>Abstract</p> <p>Background</p> <p>Activation of the peroxisome proliferator-activated receptor gamma (PPAR-γ) has been proposed as a possible neuroprotective strategy to slow down the progression of early Parkinson's disease (PD). Here we report preclinical data...
Main Authors: | Swanson Christine R, Joers Valerie, Bondarenko Viktoriya, Brunner Kevin, Simmons Heather A, Ziegler Toni E, Kemnitz Joseph W, Johnson Jeffrey A, Emborg Marina E |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-08-01
|
Series: | Journal of Neuroinflammation |
Online Access: | http://www.jneuroinflammation.com/content/8/1/91 |
Similar Items
-
A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys.
by: Sachiko Ohshima-Hosoyama, et al.
Published: (2012-01-01) -
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP
by: Christine R. Swanson, et al.
Published: (2013-01-01) -
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
by: Nordsletten Lars, et al.
Published: (2009-03-01) -
PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling
by: Nasim Dana, et al.
Published: (2019-09-01) -
Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
by: Fatemeh Amin, et al.
Published: (2021-04-01)